{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:55:17Z","timestamp":1790286917929,"version":"4.1.0"},"reference-count":237,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.humpath.2023.04.014","type":"journal-article","created":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T20:51:23Z","timestamp":1683147083000},"page":"129-143","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Cutaneous adverse reactions resulting from targeted cancer therapies: histopathologic and clinical findings"],"prefix":"10.1016","volume":"140","author":[{"given":"Dylan","family":"Haynes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6737-669X","authenticated-orcid":false,"given":"Eric E.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5625-2782","authenticated-orcid":false,"given":"Emily Y.","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2023.04.014_bib1","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.jamcollsurg.2010.10.018","article-title":"First use of intravenous chemotherapy cancer treatment: rectifying the record","volume":"212","author":"Fenn","year":"2011","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.humpath.2023.04.014_bib2","first-page":"1497","article-title":"A minute chromosome in human chronic granulogytic leukemia","volume":"132","author":"Nowell","year":"1960","journal-title":"Sceience"},{"key":"10.1016\/j.humpath.2023.04.014_bib3","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/nature03095","article-title":"Targeted cancer therapy","volume":"432","author":"Sawyers","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.humpath.2023.04.014_bib4","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/bjc.1971.33","article-title":"A new anti-oestrogenic agent in late breast cancer: an early clinical appraisal of ICI46474","volume":"25","author":"Cole","year":"1971","journal-title":"Br J Cancer"},{"key":"10.1016\/j.humpath.2023.04.014_bib5","series-title":"Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma","author":"Maloney","year":"1994"},{"key":"10.1016\/j.humpath.2023.04.014_bib6","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","article-title":"Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2023.04.014_bib7","series-title":"New drugs at FDA: CDER's new molecular entities and new therapeutic biological products","year":"2022"},{"key":"10.1016\/j.humpath.2023.04.014_bib8","first-page":"331","article-title":"Management of dermatologic toxicities associated with targeted therapy","volume":"7","author":"Lacouture","year":"2016","journal-title":"J Adv Practitioner Oncol"},{"key":"10.1016\/j.humpath.2023.04.014_bib9","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/cup.14145","article-title":"Diverse landscape of dermatologic toxicities from small-molecule inhibitor cancer therapy","volume":"49","author":"Seervai","year":"2022","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.humpath.2023.04.014_bib10","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1177\/0192623312464311","article-title":"On-target and off-target-based toxicologic effects","volume":"41","author":"Rudmann","year":"2013","journal-title":"Toxicol Pathol"},{"key":"10.1016\/j.humpath.2023.04.014_bib11","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.lungcan.2012.06.009","article-title":"Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials","volume":"78","author":"Petrelli","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.humpath.2023.04.014_bib12","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.jaad.2019.11.017","article-title":"Vitiligo under anti\u2013programmed cell death-1 therapy is associated with increased survival in melanoma patients","volume":"82","author":"Nardin","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.humpath.2023.04.014_bib13","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/jdv.16894","article-title":"Systematic review of BRAF\/MEK inhibitors-induced severe cutaneous adverse reactions (SCARs)","volume":"35","author":"Torres-Navarro","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.humpath.2023.04.014_bib14","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/DAD.0000000000000862","article-title":"Ibrutinib-induced neutrophilic dermatosis","volume":"40","author":"El Halabi","year":"2018","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.humpath.2023.04.014_bib15","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/bjd.14201","article-title":"Vemurafenib-induced toxic epidermal necrolysis: possible cross-reactivity with other sulfonamide compounds","volume":"174","author":"Bell\u00f3n","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.humpath.2023.04.014_bib16","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1159\/000439272","article-title":"Early-onset vemurafenib-induced DRESS syndrome","volume":"232","author":"Munch","year":"2016","journal-title":"Dermatology"},{"key":"10.1016\/j.humpath.2023.04.014_bib17","doi-asserted-by":"crossref","first-page":"891","DOI":"10.3892\/or.2020.7911","article-title":"Potentially life-threatening severe cutaneous adverse reactions associated with tyrosine kinase inhibitors (Review)","volume":"45","author":"Coleman","year":"2021","journal-title":"Oncol Rep"},{"key":"10.1016\/j.humpath.2023.04.014_bib18","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1200\/JCO.2007.15.7883","article-title":"Fatal toxic epidermal necrolysis associated with cetuximab in a patient with colon cancer","volume":"26","author":"Lin","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2023.04.014_bib19","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1111\/bjd.13522","article-title":"Successful switch to dabrafenib after vemurafenib-induced toxic epidermal necrolysis","volume":"172","author":"Jeudy","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.humpath.2023.04.014_bib20","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1111\/bjd.12796","article-title":"Toxic epidermal necrolysis in a patient receiving vemurafenib for treatment of metastatic malignant melanoma","volume":"170","author":"Sinha","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.humpath.2023.04.014_bib21","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.2147\/CMAR.S163391","article-title":"Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies","volume":"10","author":"Chen","year":"2018","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.humpath.2023.04.014_bib22","doi-asserted-by":"crossref","first-page":"e247","DOI":"10.1111\/ijd.14592","article-title":"Depletion of regulatory FoxP3(+) T cells in the pathogenesis of Stevens-Johnson syndrome induced by mogamulizumab","volume":"58","author":"Amakata","year":"2019","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.humpath.2023.04.014_bib23","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1034\/j.1600-0609.2002.02830.x","article-title":"Imatinib-induced acute generalized exanthematous pustulosis (AGEP) in two patients with chronic myeloid leukemia","volume":"69","author":"Schwarz","year":"2002","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.humpath.2023.04.014_bib24","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1016\/S0145-2126(03)00257-1","article-title":"Sweet's syndrome with CML cell infiltration of the skin in a patient with chronic-phase CML while taking Imatinib Mesylate","volume":"28","author":"Liu","year":"2004","journal-title":"Leuk Res"},{"key":"10.1016\/j.humpath.2023.04.014_bib25","doi-asserted-by":"crossref","first-page":"142","DOI":"10.14740\/wjon1204","article-title":"Epidermal growth factor receptor mutation frequency in squamous cell carcinoma and its diagnostic performance in cytological samples: a molecular and immunohistochemical study","volume":"10","author":"Kumari","year":"2019","journal-title":"World J Oncol"},{"key":"10.1016\/j.humpath.2023.04.014_bib26","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3393\/jksc.2011.27.3.127","article-title":"Epidermal growth factor receptor mutations in colorectal cancer patients","volume":"27","author":"Oh","year":"2011","journal-title":"J Korean Soc Coloproctol"},{"key":"10.1016\/j.humpath.2023.04.014_bib27","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/modpathol.2013.251","article-title":"High EGFR gene copy number predicts poor outcome in triple-negative breast cancer","volume":"27","author":"Park","year":"2014","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2023.04.014_bib28","doi-asserted-by":"crossref","first-page":"23","DOI":"10.21873\/invivo.11020","article-title":"Prevalence of EGFR tyrosine kinase domain mutations in head and neck squamous cell carcinoma: cohort study and systematic review","volume":"31","author":"Perisanidis","year":"2017","journal-title":"In Vivo"},{"key":"10.1016\/j.humpath.2023.04.014_bib29","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.3892\/ol.2017.5827","article-title":"High expression of EGFR predicts poor survival in patients with resected T3 stage gastric adenocarcinoma and promotes cancer cell survival","volume":"13","author":"Wang","year":"2017","journal-title":"Oncol Lett"},{"key":"10.1016\/j.humpath.2023.04.014_bib30","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1200\/JCO.2003.01.504","article-title":"Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer","volume":"21","author":"Mendelsohn","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2023.04.014_bib31","first-page":"57","article-title":"Cutaneous adverse reactions specific to epidermal growth factor receptor inhibitors","volume":"8 Spec Issue","author":"Lupu","year":"2015","journal-title":"J Med Life"},{"key":"10.1016\/j.humpath.2023.04.014_bib32","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1093\/jjco\/hyv207","article-title":"Skin problems and EGFR-tyrosine kinase inhibitor","volume":"46","author":"Kozuki","year":"2016","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.humpath.2023.04.014_bib33","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1365-4632.2010.04791.x","article-title":"Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors","volume":"50","author":"Balagula","year":"2011","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.humpath.2023.04.014_bib34","first-page":"1","article-title":"Cutaneous reactions to anticancer agents targeting the epidermal growth factor receptor: a dermatology-oncology perspective","volume":"12","author":"Lacouture","year":"2007","journal-title":"Skin Therapy Lett"},{"key":"10.1016\/j.humpath.2023.04.014_bib35","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jaad.2006.09.005","article-title":"Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management","volume":"56","author":"Hu","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.humpath.2023.04.014_bib36","article-title":"Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis","volume":"8","author":"Liu","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.humpath.2023.04.014_bib37","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1111\/cup.12202","article-title":"Histopathology of acneiform eruptions in patients treated with epidermal growth factor receptor inhibitors","volume":"40","author":"Brodell","year":"2013","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.humpath.2023.04.014_bib38","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1046\/j.1365-2133.2001.04226.x","article-title":"Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225","volume":"144","author":"Busam","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.humpath.2023.04.014_bib39","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000371821","article-title":"Acneiform rash induced by EGFR inhibitors: review of the literature and new insights","volume":"1","author":"Fabbrocini","year":"2015","journal-title":"Skin Appendage Disord"},{"key":"10.1016\/j.humpath.2023.04.014_bib40","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.critrevonc.2007.10.004","article-title":"Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients: results of an Experts Panel Meeting","volume":"66","author":"Gridelli","year":"2008","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.humpath.2023.04.014_bib41","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jaad.2005.12.016","article-title":"Nonscarring inflammatory alopecia associated with the epidermal growth factor receptor inhibitor gefitinib","volume":"55","author":"Graves","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.humpath.2023.04.014_bib42","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nrc1970","article-title":"Mechanisms of cutaneous toxicities to EGFR inhibitors","volume":"6","author":"Lacouture","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.humpath.2023.04.014_bib43","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1517\/14728222.2011.541440","article-title":"EGFR-PI3K-AKT-mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy","volume":"15","author":"Freudlsperger","year":"2011","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.humpath.2023.04.014_bib44","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.21037\/tlcr-20-141","article-title":"PI3K-AKT-mTOR pathway alterations in advanced NSCLC patients after progression on EGFR-TKI and clinical response to EGFR-TKI plus everolimus combination therapy","volume":"9","author":"Fang","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.humpath.2023.04.014_bib45","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1038\/sj.onc.1203597","article-title":"PIK3CA as an oncogene in cervical cancer","volume":"19","author":"Ma","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.humpath.2023.04.014_bib46","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1158\/1078-0432.CCR-04-2142","article-title":"Frequent mutation of the PIK3CA gene in ovarian and breast cancers","volume":"11","author":"Levine","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2023.04.014_bib47","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/sj.onc.1208304","article-title":"PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas","volume":"24","author":"Lee","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.humpath.2023.04.014_bib48","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12943-019-0954-x","article-title":"Targeting PI3K in cancer: mechanisms and advances in clinical trials","volume":"18","author":"Yang","year":"2019","journal-title":"Mol Cancer"},{"key":"10.1016\/j.humpath.2023.04.014_bib49","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1158\/0008-5472.CAN-18-2738","article-title":"AKT as a therapeutic target for CancerChallenging cancer therapy by targeting AKT","volume":"79","author":"Song","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.humpath.2023.04.014_bib50","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.3892\/ol.2017.6526","article-title":"Expression of P-EGFR and P-Akt protein in esophageal squamous cell carcinoma and its prognosis","volume":"14","author":"Shan","year":"2017","journal-title":"Oncol Lett"},{"key":"10.1016\/j.humpath.2023.04.014_bib51","doi-asserted-by":"crossref","first-page":"7482","DOI":"10.1038\/sj.onc.1209088","article-title":"The Akt\/PKB pathway: molecular target for cancer drug discovery","volume":"24","author":"Cheng","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.humpath.2023.04.014_bib52","doi-asserted-by":"crossref","first-page":"268","DOI":"10.4161\/cbt.3.3.703","article-title":"A portrait of AKT kinases: human cancer and animal models depict a family with strong individualities","volume":"3","author":"Bellacosa","year":"2004","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.humpath.2023.04.014_bib53","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.21037\/apm.2019.08.05","article-title":"Cutaneous toxicities of new targeted cancer therapies: must know for diagnosis, management, and patient-proxy empowerment","volume":"9","author":"McFarlane","year":"2020","journal-title":"Ann Palliat Med"},{"key":"10.1016\/j.humpath.2023.04.014_bib54","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s12328-016-0707-y","article-title":"Idelalisib-induced colitis and skin eruption mimicking graft-versus-host disease","volume":"10","author":"Hammami","year":"2017","journal-title":"Clin J Gastroenterol"},{"key":"10.1016\/j.humpath.2023.04.014_bib55","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/cup.13981","article-title":"Cutaneous eruption with reactive endothelial atypia due to emerging targeted cancer therapies: report of two cases with clinico-pathologic correlation","volume":"48","author":"Moya-Mart\u00ednez","year":"2021","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.humpath.2023.04.014_bib56","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jdcr.2018.03.005","article-title":"Psoriasiform eruptions secondary to phosphoinositide 3-kinase inhibition","volume":"5","author":"Dewan","year":"2019","journal-title":"JAAD case reports"},{"key":"10.1016\/j.humpath.2023.04.014_bib57","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1093\/annonc\/mdz086","volume":"30","author":"Turner","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.humpath.2023.04.014_bib58","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/annonc\/mdz177","article-title":"FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer","volume":"30","author":"Oliveira","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.humpath.2023.04.014_bib59","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/S1470-2045(17)30450-3","article-title":"Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"18","author":"Kim","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.humpath.2023.04.014_bib60","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ejca.2018.11.017","article-title":"A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction cancer","volume":"108","author":"Bang","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.humpath.2023.04.014_bib61","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s00280-016-2987-9","article-title":"Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumors","volume":"77","author":"Tamura","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.humpath.2023.04.014_bib62","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","article-title":"Tumor angiogenesis: therapeutic implications","volume":"285","author":"Folkman","year":"1971","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2023.04.014_bib63","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1634\/theoncologist.12-3-356","article-title":"FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer","volume":"12","author":"Cohen","year":"2007","journal-title":"Oncol"},{"key":"10.1016\/j.humpath.2023.04.014_bib64","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2023.04.014_bib65","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer","volume":"357","author":"Miller","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2023.04.014_bib66","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1158\/1078-0432.CCR-03-0605","article-title":"Cancer and Leukemia Group B 90206: a randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma","volume":"10","author":"Rini","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2023.04.014_bib67","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2023.04.014_bib68","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s12325-011-0007-3","article-title":"AVAglio: phase 3\u00a0trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme","volume":"28","author":"Chinot","year":"2011","journal-title":"Adv Ther"},{"key":"10.1016\/j.humpath.2023.04.014_bib69","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJMoa1309748","article-title":"Improved survival with bevacizumab in advanced cervical cancer","volume":"370","author":"Tewari","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2023.04.014_bib70","first-page":"100620","article-title":"Reassessing vascular endothelial growth factor (VEGF) in anti-angiogenic cancer therapy","volume":"32","author":"Elebiyo","year":"2022","journal-title":"Cancer Treat Res Commun"},{"key":"10.1016\/j.humpath.2023.04.014_bib71","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2022-249844","article-title":"PRIDE complex-like skin rash associated with bevacizumab","volume":"15","author":"Singh","year":"2022","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.humpath.2023.04.014_bib72","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1365-4632.2012.5658.x","article-title":"Acute and severe acne in a patient treated with bevacizumab","volume":"52","author":"Molina-Ruiz","year":"2013","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.humpath.2023.04.014_bib73","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.2169\/internalmedicine.6650-20","article-title":"Ramucirumab-related oral pyogenic granuloma: a report of two cases","volume":"60","author":"Aragaki","year":"2021","journal-title":"Intern Med"},{"key":"10.1016\/j.humpath.2023.04.014_bib74","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2019-231464","article-title":"Development of pyogenic granuloma with strong vascular endothelial growth factor receptor-2 expression during ramucirumab treatment","volume":"12","author":"Ibe","year":"2019","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.humpath.2023.04.014_bib75","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1080\/0284186X.2017.1410287","article-title":"Eruptive cherry angiomas developing in a patient treated with ramucirumab","volume":"57","author":"Espinosa Lara","year":"2018","journal-title":"Acta Oncol"},{"key":"10.1016\/j.humpath.2023.04.014_bib76","doi-asserted-by":"crossref","first-page":"454","DOI":"10.2340\/00015555-2869","article-title":"Ramucirumab-induced multiple haemangiomas of the skin: two case reports","volume":"98","author":"Kosumi","year":"2018","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.humpath.2023.04.014_bib77","doi-asserted-by":"crossref","DOI":"10.1111\/dth.12750","article-title":"Topical diltiazem for ulceration of striae distensae associated with bevacizumab therapy","volume":"32","author":"Fuentes","year":"2019","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.humpath.2023.04.014_bib78","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2019-232278","article-title":"Skin ulceration around stoma associated with aflibercept","volume":"12","author":"Fujiwara","year":"2019","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.humpath.2023.04.014_bib79","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1111\/1346-8138.13346","article-title":"Ulcerations on abdominal wound scar associated with aflibercept therapy","volume":"43","author":"Rivas-Tolosa","year":"2016","journal-title":"J Dermatol"},{"key":"10.1016\/j.humpath.2023.04.014_bib80","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1159\/000500412","article-title":"Large skin ulcer and delayed wound healing around a colostomy in a patient with metastatic colorectal cancer receiving vascular endothelial growth factor receptor-2 inhibitor therapy","volume":"12","author":"Taira","year":"2019","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.humpath.2023.04.014_bib81","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1177\/1756283X15580743","article-title":"Management of regorafenib-related toxicities: a review","volume":"8","author":"Krishnamoorthy","year":"2015","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.humpath.2023.04.014_bib82","doi-asserted-by":"crossref","first-page":"6405","DOI":"10.2147\/OTT.S156760","article-title":"Adverse events risk associated with regorafenib in the treatment of advanced solid tumors: meta-analysis of randomized controlled trials","volume":"11","author":"Yin","year":"2018","journal-title":"OncoTargets Ther"},{"key":"10.1016\/j.humpath.2023.04.014_bib83","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.jaad.2019.04.021","article-title":"Risk of hand-foot skin reaction associated with vascular endothelial growth factor-tyrosine kinase inhibitors: a meta-analysis of 57 randomized controlled trials involving 24,956 patients","volume":"83","author":"Ding","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.humpath.2023.04.014_bib84","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/1440-1681.12935","article-title":"Vascular endothelial growth factor (VEGF) antibody significantly increases the risk of hand-foot skin reaction to multikinase inhibitors (MKIs): a systematic literature review and meta-analysis","volume":"45","author":"Zhu","year":"2018","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.humpath.2023.04.014_bib85","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s12013-015-0574-z","article-title":"Bladder cancer and genetic mutations","volume":"73","author":"Zhang","year":"2015","journal-title":"Cell Biochem Biophys"},{"key":"10.1016\/j.humpath.2023.04.014_bib86","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/0391560319899011","article-title":"Bladder cancer genomics","volume":"87","author":"Siracusano","year":"2020","journal-title":"Urologia Journal"},{"key":"10.1016\/j.humpath.2023.04.014_bib87","doi-asserted-by":"crossref","first-page":"16","DOI":"10.5114\/aoms.2020.91284","article-title":"The association between fibroblast growth factor receptor 1 gene amplification and lung cancer: a meta-analysis","volume":"16","author":"Miao","year":"2020","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.humpath.2023.04.014_bib88","first-page":"5271","article-title":"Gene amplifications associated with the development of hormone-resistant prostate cancer","volume":"9","author":"Edwards","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2023.04.014_bib89","doi-asserted-by":"crossref","first-page":"16052","DOI":"10.18632\/oncotarget.14109","article-title":"Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application","volume":"8","author":"Chae","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.humpath.2023.04.014_bib90","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1006\/geno.2000.6332","article-title":"Characterization of a novel protein (FGFRL1) from human cartilage related to FGF receptors","volume":"69","author":"Wiedemann","year":"2000","journal-title":"Genomics"},{"key":"10.1016\/j.humpath.2023.04.014_bib91","doi-asserted-by":"crossref","first-page":"5750","DOI":"10.1158\/1078-0432.CCR-10-0531","article-title":"Monoclonal antibodies to fibroblast growth factor receptor 2 effectively inhibit growth of gastric tumor xenografts","volume":"16","author":"Zhao","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2023.04.014_bib92","first-page":"4508","article-title":"Neutralizing antibody to FGFR2 can act as a selective biomarker and potential therapeutic agent for gastric cancer with FGFR2 amplification","volume":"11","author":"Kim","year":"2019","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.humpath.2023.04.014_bib93","doi-asserted-by":"crossref","first-page":"860985","DOI":"10.3389\/fchem.2022.860985","article-title":"Signaling pathway and small-molecule drug discovery of FGFR: a comprehensive review","volume":"10","author":"Zheng","year":"2022","journal-title":"Front Chem"},{"key":"10.1016\/j.humpath.2023.04.014_bib94","doi-asserted-by":"crossref","first-page":"e316","DOI":"10.1002\/onco.13552","article-title":"Dermatologic adverse events associated with selective fibroblast growth factor receptor inhibitors: overview, prevention, and management guidelines","volume":"26","author":"Lacouture","year":"2021","journal-title":"Oncol"},{"key":"10.1016\/j.humpath.2023.04.014_bib95","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1111\/cup.13319","article-title":"Calcinosis cutis dermatologic toxicity associated with fibroblast growth factor receptor inhibitor for the treatment of Wilms tumor","volume":"45","author":"Arudra","year":"2018","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.humpath.2023.04.014_bib96","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1001\/jamadermatol.2018.4070","article-title":"Metastatic calcinosis cutis associated with a selective FGFR inhibitor","volume":"155","author":"Carr","year":"2019","journal-title":"JAMA dermatology"},{"key":"10.1016\/j.humpath.2023.04.014_bib97","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jdcr.2020.11.022","article-title":"Calciphylaxis associated with the fibroblast growth factor receptor inhibitor erdafitinib","volume":"7","author":"Macklis","year":"2021","journal-title":"JAAD case reports"},{"key":"10.1016\/j.humpath.2023.04.014_bib98","article-title":"Calciphylaxis cutis associated with fibroblast growth factor receptor (FGFR) inhibitor therapy: a new challenge","volume":"14","author":"Griffith","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.humpath.2023.04.014_bib99","doi-asserted-by":"crossref","DOI":"10.1038\/sj.leu.2402945","article-title":"Signal transduction mediated by the Ras\/Raf\/MEK\/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention","volume":"17","author":"Chang","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.humpath.2023.04.014_bib100","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cell.2017.06.009","article-title":"RAS proteins and their regulators in human disease","volume":"170","author":"Simanshu","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.humpath.2023.04.014_bib101","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1242\/jcs.01660","article-title":"The Ras superfamily at a glance","volume":"118","author":"Wennerberg","year":"2005","journal-title":"J Cell Sci"},{"key":"10.1016\/j.humpath.2023.04.014_bib102","first-page":"4682","article-title":"Ras oncogenes in human cancer: a review","volume":"49","author":"Bos","year":"1989","journal-title":"Cancer Res"},{"key":"10.1016\/j.humpath.2023.04.014_bib103","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1158\/1078-0432.CCR-21-3074","article-title":"FDA approval summary: sotorasib for KRAS G12C-mutated metastatic NSCLC","volume":"28","author":"Nakajima","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2023.04.014_bib104","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1056\/NEJMc2210539","article-title":"Adagrasib in non-small-cell lung cancer","volume":"387","author":"Kotecha","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2023.04.014_bib105","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2204619","article-title":"Adagrasib in non-small-cell lung cancer harboring a KRAS(G12C) mutation","volume":"387","author":"J\u00e4nne","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2023.04.014_bib106","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for lung cancers with KRAS p.G12C mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2023.04.014_bib107","doi-asserted-by":"crossref","first-page":"102205","DOI":"10.1016\/j.cbpa.2022.102205","article-title":"Mechanism and inhibition of BRAF kinase","volume":"71","author":"Gunderwala","year":"2022","journal-title":"Curr Opin Chem Biol"},{"key":"10.1016\/j.humpath.2023.04.014_bib108","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1177\/1535370220959657","article-title":"Prevalence of class I-III BRAF mutations among 114,662 cancer patients in a large genomic database","volume":"246","author":"Owsley","year":"2021","journal-title":"Exp Biol Med"},{"key":"10.1016\/j.humpath.2023.04.014_bib109","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2217\/mmt.15.21","article-title":"Dabrafenib and its use in the treatment of metastatic melanoma","volume":"2","author":"Bowyer","year":"2015","journal-title":"Melanoma Manag"},{"key":"10.1016\/j.humpath.2023.04.014_bib110","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.canlet.2015.11.015","article-title":"Encorafenib (LGX818), a potent BRAF inhibitor, induces senescence accompanied by autophagy in BRAFV600E melanoma cells","volume":"370","author":"Li","year":"2016","journal-title":"Cancer Lett"},{"key":"10.1016\/j.humpath.2023.04.014_bib111","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1634\/theoncologist.2012-0333","article-title":"Analysis of dermatologic events in vemurafenib-treated patients with melanoma","volume":"18","author":"Lacouture","year":"2013","journal-title":"Oncol"},{"key":"10.1016\/j.humpath.2023.04.014_bib112","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11864-020-0721-7","article-title":"Cutaneous adverse events of anti-PD-1 therapy and BRAF inhibitors","volume":"21","author":"Gnanendran","year":"2020","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.humpath.2023.04.014_bib113","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s40257-013-0045-5","article-title":"Cutaneous adverse events to type I BRAF inhibitors: an analysis of effects associated with each inhibitor and therapeutic time interval to onset","volume":"14","author":"Filitis","year":"2013","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.humpath.2023.04.014_bib114","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/S1470-2045(12)70413-8","article-title":"Cutaneous toxicities of RAF inhibitors","volume":"14","author":"Anforth","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.humpath.2023.04.014_bib115","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jaad.2014.07.033","article-title":"Cutaneous adverse effects of targeted therapies: Part II: inhibitors of intracellular molecular signaling pathways","volume":"72","author":"Macdonald","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.humpath.2023.04.014_bib116","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/ced.13751","article-title":"Systematic review and meta-analysis of prevalence of dermatological toxicities associated with vemurafenib treatment in patients with melanoma","volume":"44","author":"Chen","year":"2019","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.humpath.2023.04.014_bib117","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.jaad.2021.10.030","article-title":"BRAF inhibition and the spectrum of granulomatous reactions","volume":"87","author":"Pham","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.humpath.2023.04.014_bib118","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/CMR.0000000000000186","article-title":"Granulomatous nephritis and dermatitis in a patient with BRAF V600E mutant metastatic melanoma treated with dabrafenib and trametinib","volume":"25","author":"Jansen","year":"2015","journal-title":"Melanoma Res"},{"key":"10.1016\/j.humpath.2023.04.014_bib119","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/1346-8138.13255","article-title":"Cutaneous granulomatous panniculitis and sarcoidal granulomatous papular eruption in a patient with metastatic melanoma treated with a BRAF inhibitor","volume":"43","author":"Leal","year":"2016","journal-title":"J Dermatol"},{"key":"10.1016\/j.humpath.2023.04.014_bib120","first-page":"1050","article-title":"Granuloma annulare secondary to vemurafenib therapy for lung adenocarcinoma","volume":"16","author":"Jenkinson","year":"2017","journal-title":"J Drugs Dermatol JDD"},{"key":"10.1016\/j.humpath.2023.04.014_bib121","first-page":"283","article-title":"Xanthogranulomatous reaction to trametinib for metastatic malignant melanoma","volume":"102","author":"Min","year":"2018","journal-title":"Cutis"},{"key":"10.1016\/j.humpath.2023.04.014_bib122","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jaad.2012.04.008","article-title":"Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study","volume":"67","author":"Chu","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.humpath.2023.04.014_bib123","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/ajmg.c.32027","article-title":"Dermatological manifestations, management, and care in RASopathies","volume":"190","author":"Kavamura","year":"2022","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"10.1016\/j.humpath.2023.04.014_bib124","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/cup.13401","article-title":"NRAS Q61R and BRAF G466A mutations in atypical melanocytic lesions newly arising in advanced melanoma patients treated with vemurafenib","volume":"46","author":"Parekh","year":"2019","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.humpath.2023.04.014_bib125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-022-31690-w","article-title":"Qualitative differences in disease-associated MEK mutants reveal molecular signatures and aberrant signaling-crosstalk in cancer","volume":"13","author":"Kubota","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.humpath.2023.04.014_bib126","doi-asserted-by":"crossref","first-page":"113386","DOI":"10.1016\/j.ejmech.2021.113386","article-title":"Research progress of MEK1\/2 inhibitors and degraders in the treatment of cancer","volume":"218","author":"Wang","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.humpath.2023.04.014_bib127","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.pharmthera.2013.10.001","article-title":"MEK in cancer and cancer therapy","volume":"141","author":"Neuzillet","year":"2014","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.humpath.2023.04.014_bib128","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S1470-2045(12)70270-X","article-title":"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial","volume":"13","author":"Infante","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.humpath.2023.04.014_bib129","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1200\/JCO.2012.43.5966","article-title":"Phase II study of the\u00a0MEK1\/MEK2 inhibitor Trametinib in patients with metastatic\u00a0BRAF-mutant cutaneous melanoma previously treated\u00a0with or without a BRAF inhibitor","volume":"31","author":"Kim","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2023.04.014_bib130","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1007\/s10637-010-9567-3","article-title":"Dermatologic side effects associated with the MEK 1\/2 inhibitor selumetinib (AZD6244, ARRY-142886)","volume":"29","author":"Balagula","year":"2011","journal-title":"Invest N Drugs"},{"key":"10.1016\/j.humpath.2023.04.014_bib131","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1001\/jamadermatol.2014.3207","article-title":"MEK inhibitor\u2013induced dusky erythema: characteristic drug hypersensitivity manifestation in 3 patients","volume":"151","author":"Patel","year":"2015","journal-title":"JAMA dermatology"},{"key":"10.1016\/j.humpath.2023.04.014_bib132","doi-asserted-by":"crossref","DOI":"10.1007\/s12094-022-02849-0","article-title":"BRAF\/MEK inhibition in NSCLC: mechanisms of resistance and how to overcome it","author":"Tsamis","year":"2022","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.humpath.2023.04.014_bib133","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14174264","article-title":"BRAF and MEK targeted therapies in pediatric central nervous system tumors","volume":"14","author":"Talloa","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.humpath.2023.04.014_bib134","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s11912-022-01243-x","article-title":"Triplet therapy in melanoma - combined BRAF\/MEK inhibitors and anti-PD-(L)1 antibodies","volume":"24","author":"Dixon-Douglas","year":"2022","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.humpath.2023.04.014_bib135","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1080\/15569527.2018.1553180","article-title":"The risk of dermatological toxicities of combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma patients: a systematic review and meta-analysis","volume":"38","author":"Chen","year":"2019","journal-title":"Cutan Ocul Toxicol"},{"key":"10.1016\/j.humpath.2023.04.014_bib136","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/CCO.0000000000000710","article-title":"MAPK blockade, toxicities, pathogenesis and management","volume":"33","author":"Moreira","year":"2021","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.humpath.2023.04.014_bib137","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s40257-020-00539-7","article-title":"BRAF inhibitors for the treatment of papulopustular eruptions from MAPK pathway inhibitors","volume":"21","author":"Wang","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.humpath.2023.04.014_bib138","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.2c01244","article-title":"Targeting extracellular signal-regulated protein kinase 1\/2 (ERK1\/2) in cancer: an update on pharmacological small-molecule inhibitors","author":"Fu","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.humpath.2023.04.014_bib139","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1158\/2159-8290.CD-17-1119","article-title":"First-in-Class ERK1\/2 inhibitor ulixertinib (BVD-523) in patients with MAPK mutant advanced solid tumors: results of a phase I dose-escalation and expansion study","volume":"8","author":"Sullivan","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.humpath.2023.04.014_bib140","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s10637-020-01035-9","article-title":"Characterization and management of ERK inhibitor associated dermatologic adverse events: analysis from a nonrandomized trial of ulixertinib for advanced cancers","volume":"39","author":"Wu","year":"2021","journal-title":"Invest N Drugs"},{"key":"10.1016\/j.humpath.2023.04.014_bib141","first-page":"228","article-title":"Imatinib mesylate and dermatology part 2: a review of the cutaneous side effects of imatinib mesylate","volume":"5","author":"Scheinfeld","year":"2006","journal-title":"J Drugs Dermatol JDD"},{"key":"10.1016\/j.humpath.2023.04.014_bib142","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.critrevonc.2011.08.005","article-title":"Early detection, prevention and management of cutaneous adverse events due to sorafenib: recommendations from the Sorafenib Working Group","volume":"82","author":"Bracarda","year":"2012","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.humpath.2023.04.014_bib143","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1586\/14737140.2015.985660","article-title":"Risk of mucocutaneous toxicities in patients with solid tumors treated with sunitinib: a critical review and meta analysis","volume":"15","author":"Abdel-Rahman","year":"2015","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.humpath.2023.04.014_bib144","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s40257-016-0197-1","article-title":"Multikinase inhibitor-induced hand-foot skin reaction: a review of clinical presentation, pathogenesis, and management","volume":"17","author":"Chanprapaph","year":"2016","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.humpath.2023.04.014_bib145","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1093\/annonc\/mdv244","article-title":"Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management","volume":"26","author":"McLellan","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.humpath.2023.04.014_bib146","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/ced.12694","article-title":"Incidence and\u00a0risk of hand-foot skin reaction with cabozantinib, a novel multikinase inhibitor: a meta-analysis","volume":"41","author":"Belum","year":"2016","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.humpath.2023.04.014_bib147","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1080\/17512433.2019.1689122","article-title":"Sorafenib-associated hand-foot skin reaction: practical advice on diagnosis, mechanism, prevention, and management","volume":"12","author":"Ai","year":"2019","journal-title":"Expet Rev Clin Pharmacol"},{"key":"10.1016\/j.humpath.2023.04.014_bib148","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1007\/s10637-011-9652-2","article-title":"The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis","volume":"30","author":"Balagula","year":"2012","journal-title":"Invest N Drugs"},{"key":"10.1016\/j.humpath.2023.04.014_bib149","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3816\/CGC.2009.n.002","article-title":"Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis","volume":"7","author":"Chu","year":"2009","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.humpath.2023.04.014_bib150","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/j.1365-2133.2007.08357.x","article-title":"Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy","volume":"158","author":"Yang","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.humpath.2023.04.014_bib151","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/CAD.0000000000001140","article-title":"Tyrosine kinase inhibitors-associated pyoderma gangrenosum, a systematic review of published case reports","volume":"33","author":"Khoshnam-Rad","year":"2022","journal-title":"Anti Cancer Drugs"},{"key":"10.1016\/j.humpath.2023.04.014_bib152","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14461","article-title":"Sweet syndrome as an adverse reaction to tyrosine kinase inhibitors: a review","volume":"34","author":"Yang","year":"2021","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.humpath.2023.04.014_bib153","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s40257-017-0308-7","article-title":"Drug-induced pyoderma gangrenosum: a review","volume":"19","author":"Wang","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.humpath.2023.04.014_bib154","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/cup.12273","article-title":"Sweet syndrome following vemurafenib therapy for recurrent cholangiocarcinoma","volume":"41","author":"Pattanaprichakul","year":"2014","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.humpath.2023.04.014_bib155","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1182\/blood-2013-01-478172","article-title":"FLT3 inhibitor-induced neutrophilic dermatosis","volume":"122","author":"Fathi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2023.04.014_bib156","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1001\/archderm.141.3.368","article-title":"Imatinib-induced sweet syndrome in a patient with chronic myeloid leukemia","volume":"141","author":"Ayirookuzhi","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.humpath.2023.04.014_bib157","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1001\/archderm.144.3.361","article-title":"Bullous sweet syndrome in a patient with t(9;22)(q34;q11)-positive chronic myeloid leukemia treated with the tyrosine kinase inhibitor nilotinib: interphase cytogenetic detection of BCR-ABL- positive lesional cells","volume":"144","author":"Kaune","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.humpath.2023.04.014_bib158","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","article-title":"Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial","volume":"30","author":"Wells","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2023.04.014_bib159","article-title":"Risk of rash associated with vandetanib treatment in non-small-cell lung cancer patients: a meta-analysis of 9 randomized controlled trials","volume":"96","author":"Liu","year":"2017","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.humpath.2023.04.014_bib160","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1001\/2013.jamadermatol.192","article-title":"A new spectrum of skin toxic effects associated with the multikinase inhibitor vandetanib","volume":"148","author":"Giacchero","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.humpath.2023.04.014_bib161","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1001\/archdermatol.2009.177","article-title":"Cutaneous pigmentation after photosensitivity induced by vandetanib therapy","volume":"145","author":"Kong","year":"2009","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.humpath.2023.04.014_bib162","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.abd.2021.08.010","article-title":"Phototoxic drug eruption induced by vandetanib used for the treatment of metastatic medullary thyroid cancer","volume":"97","author":"Bostan","year":"2022","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.humpath.2023.04.014_bib163","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.abd.2021.05.010","article-title":"Vandetanib induced phototoxic reaction progressed to toxic epidermal necrolysis","volume":"97","author":"Gul","year":"2022","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.humpath.2023.04.014_bib164","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/287795a0","article-title":"Mutations affecting segment number and polarity in Drosophila","volume":"287","author":"N\u00fcsslein-Volhard","year":"1980","journal-title":"Nature"},{"key":"10.1016\/j.humpath.2023.04.014_bib165","doi-asserted-by":"crossref","first-page":"60684","DOI":"10.18632\/oncotarget.19527","article-title":"The Hedgehog-GLI pathway in embryonic development and cancer: implications for pulmonary oncology therapy","volume":"8","author":"Armas-L\u00f3pez","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.humpath.2023.04.014_bib166","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/34201","article-title":"Activating Smoothened mutations in sporadic basal-cell carcinoma","volume":"391","author":"Xie","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.humpath.2023.04.014_bib167","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1126\/science.272.5268.1668","article-title":"Human homolog of patched, a candidate gene for the basal cell nevus syndrome","volume":"272","author":"Johnson","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.humpath.2023.04.014_bib168","article-title":"Hedgehog pathway inhibitors as targeted cancer therapy and strategies to overcome drug resistance","volume":"23","author":"Nguyen","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.humpath.2023.04.014_bib169","article-title":"The expression of the renin-angiotensin-aldosterone system in the skin and its effects on skin physiology and pathophysiology","volume":"70","author":"Aleksiejczuk","year":"2019","journal-title":"J Physiol Pharmacol"},{"key":"10.1016\/j.humpath.2023.04.014_bib170","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1111\/bjd.18552","article-title":"Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study","volume":"182","author":"Dummer","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.humpath.2023.04.014_bib171","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1634\/theoncologist.2016-0186","article-title":"Characterization and management of hedgehog pathway inhibitor-related adverse events in patients with advanced basal cell carcinoma","volume":"21","author":"Lacouture","year":"2016","journal-title":"Oncol"},{"key":"10.1016\/j.humpath.2023.04.014_bib172","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1159\/000510121","article-title":"Vismodegib-induced alopecia: trichoscopic and confocal microscopy evaluation","volume":"6","author":"Cantelli","year":"2020","journal-title":"Skin Appendage Disord"},{"key":"10.1016\/j.humpath.2023.04.014_bib173","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/jid.2008.279","article-title":"An essential role for dermal primary cilia in hair follicle morphogenesis","volume":"129","author":"Lehman","year":"2009","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.humpath.2023.04.014_bib174","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/bjd.13619","article-title":"Hair loss and Hedgehog inhibitors: a class effect?","volume":"173","author":"Ferguson","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.humpath.2023.04.014_bib175","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jaad.2015.03.013","article-title":"A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma","volume":"73","author":"Sofen","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.humpath.2023.04.014_bib176","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1111\/bjd.13630","article-title":"Persistent alopecia induced by vismodegib","volume":"172","author":"Alkeraye","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.humpath.2023.04.014_bib177","first-page":"E19","article-title":"Reversible cutaneous side effects of vismodegib treatment","volume":"99","author":"Kwong","year":"2017","journal-title":"Cutis"},{"key":"10.1016\/j.humpath.2023.04.014_bib178","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1001\/jamadermatol.2015.4330","article-title":"Increased risk of cutaneous squamous cell carcinoma after vismodegib therapy for basal cell carcinoma","volume":"152","author":"Mohan","year":"2016","journal-title":"JAMA dermatology"},{"key":"10.1016\/j.humpath.2023.04.014_bib179","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.jaad.2017.03.038","article-title":"Risk of cutaneous squamous cell carcinoma after treatment of basal cell carcinoma with vismodegib","volume":"77","author":"Bhutani","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.humpath.2023.04.014_bib180","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1001\/jamadermatol.2013.1798","article-title":"New onset of keratoacanthomas after vismodegib treatment for locally advanced basal cell carcinomas: a report of 2 cases","volume":"149","author":"Aasi","year":"2013","journal-title":"JAMA dermatology"},{"key":"10.1016\/j.humpath.2023.04.014_bib181","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1001\/jamadermatol.2014.583","article-title":"Two different scenarios of squamous cell carcinoma within advanced Basal cell carcinomas: cases illustrating the importance of serial biopsy during vismodegib usage","volume":"150","author":"Zhu","year":"2014","journal-title":"JAMA dermatology"},{"key":"10.1016\/j.humpath.2023.04.014_bib182","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.canlet.2017.09.052","article-title":"CNOT2 promotes proliferation and angiogenesis via VEGF signaling in MDA-MB-231 breast cancer cells","volume":"412","author":"Sohn","year":"2018","journal-title":"Cancer Lett"},{"key":"10.1016\/j.humpath.2023.04.014_bib183","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/intimm\/dxu079","article-title":"CCR4 and its ligands: from bench to bedside","volume":"27","author":"Yoshie","year":"2015","journal-title":"Int Immunol"},{"key":"10.1016\/j.humpath.2023.04.014_bib184","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1158\/1078-0432.CCR-14-0830","article-title":"Reduction of regulatory T cells by Mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive\/refractory mycosis\u00a0fungoides and S\u00e9zary syndrome","volume":"21","author":"Ni","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2023.04.014_bib185","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.humpath.2023.04.014_bib186","doi-asserted-by":"crossref","first-page":"940052","DOI":"10.3389\/fimmu.2022.940052","article-title":"Exhaust the exhausters: targeting regulatory T cells in the tumor microenvironment","volume":"13","author":"McRitchie","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.humpath.2023.04.014_bib187","first-page":"827","article-title":"Phase Ib study on the humanized anti-CCR4 antibody, KW-0761, in advanced solid tumors","volume":"83","author":"Saito","year":"2021","journal-title":"Nagoya J Med Sci"},{"key":"10.1016\/j.humpath.2023.04.014_bib188","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1158\/1078-0432.CCR-21-2781","article-title":"Mogamulizumab in combination with nivolumab in a phase I\/II study of patients with locally advanced or metastatic solid tumors","volume":"28","author":"Hong","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2023.04.014_bib189","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.1158\/1078-0432.CCR-20-0328","article-title":"Mogamulizumab in combination with durvalumab or tremelimumab in patients with advanced solid tumors: a phase I study","volume":"26","author":"Zamarin","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2023.04.014_bib190","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1186\/s40425-019-0815-6","article-title":"A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors","volume":"7","author":"Cohen","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.humpath.2023.04.014_bib191","doi-asserted-by":"crossref","first-page":"6614","DOI":"10.1158\/1078-0432.CCR-19-1090","article-title":"A phase I study of the anti-CC chemokine receptor 4 antibody, mogamulizumab, in combination with nivolumab in patients with advanced or metastatic solid tumors","volume":"25","author":"Doi","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2023.04.014_bib192","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1007\/s12185-017-2270-9","article-title":"Safety and efficacy of mogamulizumab in patients with adult T-cell leukemia-lymphoma in Japan: interim results of postmarketing all-case surveillance","volume":"106","author":"Ishitsuka","year":"2017","journal-title":"Int J Hematol"},{"key":"10.1016\/j.humpath.2023.04.014_bib193","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1001\/jamadermatol.2021.0877","article-title":"Clinical characterization of mogamulizumab-associated rash during treatment of mycosis fungoides or s\u00e9zary syndrome","volume":"157","author":"Hirotsu","year":"2021","journal-title":"JAMA dermatology"},{"key":"10.1016\/j.humpath.2023.04.014_bib194","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1097\/PAS.0000000000001587","article-title":"Histopathologic characterization of mogamulizumab-associated rash","volume":"44","author":"Wang","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.humpath.2023.04.014_bib195","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/ced.13539","article-title":"CD8+ T cell-mediated interface dermatitis during combination chemotherapy with mogamulizumab in a patient with adult T-cell leukaemia\/lymphoma","volume":"43","author":"Tani","year":"2018","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.humpath.2023.04.014_bib196","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1001\/jamadermatol.2019.0369","article-title":"Mogamulizumab-associated cutaneous granulomatous drug eruption mimicking mycosis fungoides but possibly indicating durable clinical response","volume":"155","author":"Chen","year":"2019","journal-title":"JAMA dermatology"},{"key":"10.1016\/j.humpath.2023.04.014_bib197","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1111\/jdv.14797","article-title":"Mogamulizumab-induced photosensitivity in patients with mycosis fungoides and other T-cell neoplasms","volume":"32","author":"Masuda","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.humpath.2023.04.014_bib198","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0092-8674(93)90667-F","article-title":"Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia","volume":"72","author":"Tsukada","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.humpath.2023.04.014_bib199","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrc3702","article-title":"Targeting Bruton's tyrosine kinase in B cell malignancies","volume":"14","author":"Hendriks","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.humpath.2023.04.014_bib200","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s13045-022-01353-w","article-title":"BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies","volume":"15","author":"Alu","year":"2022","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.humpath.2023.04.014_bib201","doi-asserted-by":"crossref","first-page":"26258","DOI":"10.1074\/jbc.M301484200","article-title":"Bruton's tyrosine kinase is a Toll\/interleukin-1 receptor domain-binding protein that participates in nuclear factor \u03baB activation by Toll-like receptor 4","volume":"278","author":"Jefferies","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.humpath.2023.04.014_bib202","first-page":"2590","article-title":"The clinically active BTK inhibitor PCI-32765 targets B-cell receptor\u2013and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia","volume":"119","author":"de Rooij","year":"2012","journal-title":"Blood J Am Soc Hematol"},{"key":"10.1016\/j.humpath.2023.04.014_bib203","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1002\/eji.1830231210","article-title":"The Bruton's tyrosine kinase gene is expressed throughout B cell differentiation, from early precursor B cell stages preceding immunoglobulin gene rearrangement up to mature B cell stages","volume":"23","author":"de Weers","year":"1993","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.humpath.2023.04.014_bib204","doi-asserted-by":"crossref","first-page":"557","DOI":"10.4049\/jimmunol.152.2.557","article-title":"Expression of Bruton's agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells","volume":"152","author":"Smith","year":"1994","journal-title":"J Immunol"},{"key":"10.1016\/j.humpath.2023.04.014_bib205","doi-asserted-by":"crossref","first-page":"10606","DOI":"10.1073\/pnas.91.22.10606","article-title":"Bruton tyrosine kinase is tyrosine phosphorylated and activated in pre-B lymphocytes and receptor-ligated B cells","volume":"91","author":"Aoki","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.humpath.2023.04.014_bib206","first-page":"574","article-title":"Expression of the X-linked agammaglobulinemia gene, btk in B-cell acute lymphoblastic leukemia","volume":"8","author":"Katz","year":"1994","journal-title":"Leukemia"},{"key":"10.1016\/j.humpath.2023.04.014_bib207","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/1346-8138.15154","article-title":"Atopic dermatitis without serum immunoglobulin E elevation or loss-of-function filaggrin gene mutation in a patient with X-linked agammaglobulinemia","volume":"47","author":"Yamazaki","year":"2020","journal-title":"J Dermatol"},{"key":"10.1016\/j.humpath.2023.04.014_bib208","doi-asserted-by":"crossref","first-page":"476","DOI":"10.5021\/ad.2017.29.4.476","article-title":"Pyoderma gangrenosum in a patient with X-linked agammaglobulinemia","volume":"29","author":"Tan","year":"2017","journal-title":"Ann Dermatol"},{"key":"10.1016\/j.humpath.2023.04.014_bib209","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s40257-020-00535-x","article-title":"Dermatological toxicities of bruton's tyrosine kinase inhibitors","volume":"21","author":"Sibaud","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.humpath.2023.04.014_bib210","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/bjh.14302","article-title":"Ibrutinib-associated rash: a single-centre experience of clinicopathological features and management","volume":"180","author":"Iberri","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.humpath.2023.04.014_bib211","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1001\/jamaoncol.2015.0457","article-title":"Panniculitis in patients undergoing treatment with the Bruton tyrosine kinase inhibitor ibrutinib for lymphoid leukemias","volume":"1","author":"Fabbro","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.humpath.2023.04.014_bib212","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jdcr.2017.01.027","article-title":"Lower extremity ecchymotic nodules in a patient being treated with ibrutinib for chronic lymphocytic leukemia","volume":"3","author":"Hammel","year":"2017","journal-title":"JAAD case reports"},{"key":"10.1016\/j.humpath.2023.04.014_bib213","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/DAD.0000000000001391","article-title":"Ibrutinib and pyoderma gangrenosum in a patient with B-cell chronic lymphocytic leukemia","volume":"42","author":"Giovanni","year":"2020","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.humpath.2023.04.014_bib214","doi-asserted-by":"crossref","DOI":"10.3892\/ijo.2021.5273","article-title":"Role of nectin-4 protein in cancer (review)","volume":"59","author":"Liu","year":"2021","journal-title":"Int J Oncol"},{"key":"10.1016\/j.humpath.2023.04.014_bib215","doi-asserted-by":"crossref","first-page":"174516","DOI":"10.1016\/j.ejphar.2021.174516","article-title":"Nectin cell adhesion molecule-4 (NECTIN-4): a potential target for cancer therapy","volume":"911","author":"Chatterjee","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.humpath.2023.04.014_bib216","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1080\/13543784.2019.1667332","article-title":"Enfortumab Vedotin, a fully human monoclonal antibody against Nectin 4 conjugated to monomethyl auristatin E for metastatic urothelial Carcinoma","volume":"28","author":"McGregor","year":"2019","journal-title":"Expet Opin Invest Drugs"},{"key":"10.1016\/j.humpath.2023.04.014_bib217","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jdin.2022.10.004","article-title":"Characterization of cutaneous adverse events to enfortumab vedotin: a retrospective case-control study","volume":"10","author":"Shahin","year":"2023","journal-title":"JAAD Int"},{"key":"10.1016\/j.humpath.2023.04.014_bib218","article-title":"Cutaneous toxicity with suprabasal blisters and dyskeratosis following administration of enfortumab vedotin","author":"Hasui","year":"2022","journal-title":"J Dermatol"},{"key":"10.1016\/j.humpath.2023.04.014_bib219","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1097\/DAD.0000000000002255","article-title":"Enfortumab vedotin-associated toxic epidermal necrolysis-like toxic erythema of chemotherapy","volume":"44","author":"Birmingham","year":"2022","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.humpath.2023.04.014_bib220","doi-asserted-by":"crossref","first-page":"e1009","DOI":"10.1111\/jdv.18406","article-title":"Enfortumab vedotin-induced cutaneous adverse events manifesting as miliaria-like eruptions with the presence of keratinocyte apoptosis in clinically intact skin","volume":"36","author":"Oya","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.humpath.2023.04.014_bib221","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ejca.2022.02.019","article-title":"Life-threatening skin reaction with enfortumab vedotin: six cases","volume":"167","author":"Guerrois","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.humpath.2023.04.014_bib222","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ejca.2022.02.020","article-title":"Keratinocyte apoptosis was present in clinically intact skin in a patient treated with enfortumab vedotin","volume":"167","author":"Oya","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.humpath.2023.04.014_bib223","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jdcr.2022.01.005","article-title":"Severe cutaneous drug toxicity following enfortumab vedotin treatment for metastatic urothelial carcinoma","volume":"21","author":"Enescu","year":"2022","journal-title":"JAAD case reports"},{"key":"10.1016\/j.humpath.2023.04.014_bib224","doi-asserted-by":"crossref","first-page":"128","DOI":"10.4103\/idoj.idoj_178_21","article-title":"Enfortumab vedotin-induced toxic epidermal necrolysis: a rare fatal adverse reaction","volume":"13","author":"Bansal","year":"2022","journal-title":"Indian Dermatol Online J"},{"key":"10.1016\/j.humpath.2023.04.014_bib225","doi-asserted-by":"crossref","first-page":"801199","DOI":"10.3389\/fonc.2021.801199","article-title":"Cutaneous toxicity associated with enfortumab vedotin: a real-word study leveraging U.S. Food and drug administration adverse event reporting system","volume":"11","author":"Yang","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.humpath.2023.04.014_bib226","first-page":"1781","article-title":"A distinctive bullous skin reaction associated with enfortumab vedotin-ejfv treatment for metastatic urothelial cancer: a case report","volume":"19","author":"Krause","year":"2021","journal-title":"Journal der Deutschen Dermatologischen Gesellschaft = J German Soc Dermatol: JDDG"},{"key":"10.1016\/j.humpath.2023.04.014_bib227","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1001\/jamadermatol.2021.3450","article-title":"Postmarketing cases of enfortumab vedotin-associated skin reactions reported as Stevens-johnson syndrome or toxic epidermal necrolysis","volume":"157","author":"Nguyen","year":"2021","journal-title":"JAMA dermatology"},{"key":"10.1016\/j.humpath.2023.04.014_bib228","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jdcr.2021.05.020","article-title":"Cutaneous reactions with enfortumab vedotin: a case series and review of the literature","volume":"14","author":"Dobry","year":"2021","journal-title":"JAAD case reports"},{"key":"10.1016\/j.humpath.2023.04.014_bib229","doi-asserted-by":"crossref","first-page":"621591","DOI":"10.3389\/fonc.2021.621591","volume":"11","author":"Viscuse","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.humpath.2023.04.014_bib230","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jdcr.2020.10.020","article-title":"A rare presentation of enfortumab vedotin-induced toxic epidermal necrolysis","volume":"7","author":"Francis","year":"2021","journal-title":"JAAD case reports"},{"key":"10.1016\/j.humpath.2023.04.014_bib231","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/j.jaad.2020.11.067","article-title":"Clinicopathologic characterization of enfortumab vedotin-associated cutaneous toxicity in patients with urothelial carcinoma","volume":"85","author":"Hirotsu","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.humpath.2023.04.014_bib232","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1111\/1346-8138.15577","article-title":"Severe eczematoid and lichenoid eruption with full-thickness epidermal necrosis developing from metastatic urothelial cancer treated with enfortumab vedotin","volume":"47","author":"Sasaki","year":"2020","journal-title":"J Dermatol"},{"key":"10.1016\/j.humpath.2023.04.014_bib233","article-title":"Flexural exanthema from enfortumab vedotin","volume":"12","author":"Keerty","year":"2020","journal-title":"Cureus"},{"key":"10.1016\/j.humpath.2023.04.014_bib234","doi-asserted-by":"crossref","DOI":"10.5070\/D3252042890","article-title":"Cutaneous toxicity associated with enfortumab vedotin treatment of metastatic urothelial carcinoma","volume":"25","author":"Wu","year":"2019","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.humpath.2023.04.014_bib235","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.clindermatol.2020.06.007","article-title":"Adverse cutaneous reactions to chemotherapeutic drugs","volume":"38","author":"Haynes","year":"2020","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.humpath.2023.04.014_bib236","doi-asserted-by":"crossref","first-page":"26","DOI":"10.4149\/neo_2013_004","article-title":"Skin rash as useful marker of erlotinib efficacy in NSCLC and its impact on clinical practice","volume":"60","author":"Fiala","year":"2013","journal-title":"Neoplasma"},{"key":"10.1016\/j.humpath.2023.04.014_bib237","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/1756-9966-29-95","article-title":"Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib","volume":"29","author":"Jain","year":"2010","journal-title":"J Exp Clin Cancer Res"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817723001004?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817723001004?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T16:43:01Z","timestamp":1758645781000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817723001004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":237,"alternative-id":["S0046817723001004"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2023.04.014","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cutaneous adverse reactions resulting from targeted cancer therapies: histopathologic and clinical findings","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2023.04.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}